Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

193 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Continuous Clinical Response Is Associated With a Change of Disease Course in Patients With Moderate to Severe Ulcerative Colitis Treated With Golimumab.
Reinisch W, Colombel JF, Gibson PR, Rutgeerts P, Sandborn WJ, Tarabar D, Huyck S, Khalifa A, Marano C, Philip G, Yao R, Zhang H, Cornillie F. Reinisch W, et al. Among authors: philip g. Inflamm Bowel Dis. 2019 Jan 1;25(1):163-171. doi: 10.1093/ibd/izy229. Inflamm Bowel Dis. 2019. PMID: 29982631 Clinical Trial.
Five-year Safety Data From OPUS, a European Observational Safety Registry for Adults With Ulcerative Colitis Treated With Originator Infliximab [Remicade®] or Conventional Therapy.
Panés J, Lindsay JO, Teich N, Lindgren S, Colombel JF, Cornillie F, Flynn HA, Huyck S, Stryszak P, Yao R, Philip G, Reinisch W. Panés J, et al. Among authors: philip g. J Crohns Colitis. 2019 Sep 19;13(9):1148-1157. doi: 10.1093/ecco-jcc/jjz048. J Crohns Colitis. 2019. PMID: 30809631
Patient-reported continuous clinical response to golimumab in adults with moderately to severely active ulcerative colitis: results from GO OBSERVE, a real-world European observational study.
Ferrante M, Schirbel A, Pierik MJ, Haas T, Flamant M, Khalifa A, Philip G, Cornillie F, Meehan AG, Govoni M. Ferrante M, et al. Among authors: philip g. Eur J Gastroenterol Hepatol. 2022 Jun 1;34(6):646-654. doi: 10.1097/MEG.0000000000002374. Epub 2022 Apr 8. Eur J Gastroenterol Hepatol. 2022. PMID: 35412484
Soluble human Suppression of Tumorigenicity 2 is associated with endoscopic activity in patients with moderate-to-severe ulcerative colitis treated with golimumab.
Magro F, Lopes S, Silva M, Coelho R, Portela F, Branquinho D, Correia L, Fernandes S, Cravo M, Caldeira P, Tavares de Sousa H, Patita M, Lago P, Ramos J, Afonso J, Redondo I, Machado P, Philip G, Lopes J, Carneiro F. Magro F, et al. Among authors: philip g. Therap Adv Gastroenterol. 2019 Aug 30;12:1756284819869141. doi: 10.1177/1756284819869141. eCollection 2019. Therap Adv Gastroenterol. 2019. PMID: 31516554 Free PMC article.
193 results